

Impact of COVID-19 on the management and outcomes of ureteric stones in the UK: a multicentre retrospective study

Matthew H V Byrne^{1,2}, Fanourios Georgiades^{3,4}, Alexander Light⁵, Catherine E Lovegrove^{1,2}, Catherine Dominic⁶, Josephine Rahman⁷, Senthoooran Kathiravelupillai⁸, Tobias Klatte⁹, Kasra Saeb-Parsy⁴, Rajeev Kumar¹, Sarah Howles^{1,2}, Grant D Stewart^{3,4}, Ben Turney^{1,2}, Oliver Wiseman⁴ on behalf of the COVID Stones Collaborative*

Affiliations:

¹Nuffield Department of Surgical Sciences, University of Oxford, UK

²Oxford University Hospitals NHS Foundation Trust, UK

³Department of Surgery, University of Cambridge, UK

⁴Cambridge University Hospitals NHS Foundation Trust, UK

⁵Department of Surgery and Cancer, Imperial College London, UK

⁶Barts and the London School of Medicine, Queen Mary University of London, UK

⁷University of Bristol, UK

⁸School of Clinical Medicine, University of Cambridge, UK

⁹Department of Urology, Charité - Universitätsmedizin Berlin, Germany

*Collaborating authors are listed in Appendix A

Corresponding author

Name: Matthew Byrne

Email address: matthew.byrne@nds.ox.ac.uk

Full Institution address: Oxford University Hospitals NHS Foundation Trust, UK

Institution post code: OX3 7LE

Twitter: @mhvbyrne

Authorship: MHVB and FG were responsible for conceptualisation. All authors were responsible for writing the first draft and revisions. AL, CD, JR, RK, and Members of the COVID Stone Collaborative were responsible for data collection. MHVB was responsible for data analysis. SH, GDS, BT, and OW were responsible for supervision. BT and OW are the guarantors. All authors have seen and approved the final version.

Sources of support: None

Conflicts of interests: GDS - educational grants from Pfizer, AstraZeneca and Intuitive Surgical; consultancy fees from Pfizer, Merck, EUSA Pharma and CMR Surgical; Speaker fees from Pfizer; Trustee The Urology Foundation and Kidney Cancer UK; Travel expenses from Pfizer. OJW: consulting fees: Boston Scientific, EMS, Coloplast, Ambu, Astellas. Speaker fees: Education Boston Scientific, EMS, Coloplast, Ambu. Research grants Coloplast, EMSI; Trustee BAUS, Treasurer BAUS. BT: consulting fees: Boston Scientific; Speaker fees: Boston Scientific, Devicare, BJUI (subeditor); Data safety monitoring / advisory board: Boston Scientific.

Data availability: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Ethical Approval: We followed NHS Health Research Authority guidance and the study did not require ethical approval. Each participating site obtained local audit approval.

Acknowledgements: None

Study type: Retrospective cohort study

Running Title: COVID Stones study

Key words: Urolithiasis, ureteric stone, ureteral stone, COVID-19, patient outcomes, management, conservative management, spontaneous stone passage, ESWL, ureteroscopy, nephrostomy

Number of figures: 1 (+ 0 supplementary)

Number of tables: 3 (+ 1 supplementary)

Word count: 2079

1 **ABSTRACT**

2 **Objectives:** To determine if management of ureteric stones in the United Kingdom
3 changed during the COVID-19 pandemic and whether this affected patient
4 outcomes.

5
6 **Patients and methods:** We conducted a multicentre retrospective study of adults
7 with CT-proven ureteric stone disease at 39 UK hospitals during a pre-pandemic
8 period (23/3/19 to 22/6/19) and a period during the pandemic (the 3-month period
9 after the first SARS-CoV-2 case at individual sites). The primary outcome was
10 success of primary treatment modality, defined as no further treatment required for
11 the index ureteric stone. Our study protocol was published prior to data collection.

12
13 **Results:** A total of 3735 patients were included (pre-pandemic=1956 patients;
14 pandemic=1779 patients). Stone size was similar between groups ($p>0.05$). During
15 the pandemic, patients had lower hospital admission rates (pre-pandemic=54.0% vs
16 pandemic=46.5%, $p<0.001$), shorter length of stay (mean=4.1 vs. 3.3 days, $p=0.02$),
17 and higher rates of use of medical expulsive therapy (17.4% vs. 25.4%, $p<0.001$). In
18 patients who received interventional management (pre-pandemic $n=787$ vs.
19 pandemic $n=685$), rates of ESWL (22.7% vs. 34.1%, $p<0.001$) and nephrostomy
20 were higher (7.1% vs. 10.5%, $p=0.03$); and rates of ureteroscopy (57.2% vs. 47.5%,
21 $p<0.001$), stent insertion (68.4% vs. 54.6%, $p<0.001$), and general anaesthetic
22 (92.2% vs. 76.2%, $p<0.001$) were lower.

23
24 There was no difference in success of primary treatment modality between patient
25 cohorts (pre-pandemic=73.8% vs. pandemic=76.1%, $P=0.11$), nor when patients

26 were stratified by treatment modality or stone size. Rates of operative complications,
27 30-day mortality, and readmission and renal function at 6 months did not differ
28 between the data collection periods.

29

30 **Conclusions:** During the COVID-19 pandemic, there were lower admission rates
31 and fewer invasive procedures performed. Despite this, there were no differences in
32 treatment success or outcomes. Our findings indicate that clinicians can safely adopt
33 management strategies developed during the pandemic to treat more patients
34 conservatively and in the community.

35 INTRODUCTION

36 Nephrolithiasis is a major clinical and economic health challenge. Up to 20% of men
37 and 10% of women are affected by stone disease ^{1,2}. It is responsible for over
38 85,000 hospital episodes in the UK and costs the UK National Health Service (NHS)
39 an estimated £190-324 million per year ³.

40

41 The management of ureteric stones can be conservative, as most stones smaller
42 than 5mm pass spontaneously ⁴. However, interventions such as extracorporeal
43 shockwave lithotripsy (ESWL) or ureteroscopic (URS) laser lithotripsy may be
44 required. Untreated stone disease can result in refractory pain, sepsis, renal failure,
45 and death ⁵. The UK National Institute for Health and Care Excellence (NICE)
46 guidelines published in 2019 recommend that adults with ureteric stones measuring
47 less than 10mm should be treated with ESWL and URS is recommended as a
48 second line alternative. For ureteric stones measuring between 10 and 20mm, URS
49 should be offered as first line treatment, and ESWL can be considered if local
50 facilities will allow stone clearance to be achieved within 4 weeks ⁶.

51

52 In March 2020, COVID-19 was declared a pandemic by the World Health
53 Organisation (WHO), and measures were introduced across the world to mitigate the
54 spread of infection ⁷. There was worldwide disruption to healthcare provision,
55 including increased pressures on healthcare services and the cancellation of elective
56 procedures ⁸. The multicentre, international COVIDSurg study demonstrated that
57 perioperative infection with the SARS-CoV-2 virus was associated with an
58 unadjusted 30-day mortality of 23.8% ⁹. In light of this, and as a result of reduced
59 access to operating theatres, recommendations were made to favour non-operative

60 management strategies ^{8,10-12}. Furthermore, during the peak of the pandemic in the
61 UK, non-COVID-19 related Emergency Department attendances fell dramatically as
62 patients delayed or avoided presentation to hospital due to fear of infection ¹³.

63

64 The existing body of literature around COVID-19 and endourology discusses
65 alterations required of clinical care to accommodate the widespread disruption to
66 healthcare services due to COVID-19. However, these articles were written at the
67 start of the COVID-19 pandemic and do not discuss whether these suggested
68 changes to treatment algorithms manifested during the pandemic or what their
69 impact on outcomes were ^{11,12,14}.

70

71 We hypothesised that during COVID-19 there were delays in patient presentation
72 resulting in higher rates of AKI and sepsis and that non-invasive management
73 options such as observation, ESWL, and alternatives to general anaesthesia were
74 used more frequently, resulting in higher rates of failed index management and
75 subsequent change in treatment modality and/or re-presentation to hospital. We
76 sought to test this hypothesis by undertaking a multicentre, retrospective study to
77 determine how management of ureteric stones changed during the COVID-19
78 pandemic in the United Kingdom and define how changes in management affected
79 patient outcomes.

80 **METHODS**

81 **Study design**

82 We conducted a multicentre, retrospective cohort study of the management and
83 outcomes of patients presenting with ureteric stones before and during the COVID-
84 19 pandemic at 39 hospitals in the United Kingdom.

85

86 Our protocol was published prior to data collection ¹⁵. We followed principles of the
87 trainee-led collaborative research model ¹⁶, coordinated by the COVID Stones
88 Collaborative; and the STROBE (STrengthening the Reporting of OBservational
89 studies in Epidemiology) guidelines ¹⁷ (Appendix B). NHS Health Research Authority
90 guidance was followed, and each participating site obtained local audit approval.

91

92 Patients aged ≥ 18 years with ureteric stone disease confirmed on contrast or non-
93 contrast computed tomography (CT) imaging were identified via retrospective review
94 of all abdominal CT scans undertaken during relevant data collection periods.

95 Patients with non-ureteric stone disease were excluded.

96 **Data collection**

97 Data was collected during two time periods: a pre-pandemic period from 23/3/19 to
98 22/6/19; and a period during the pandemic, which was defined as the 3-month period
99 after the first SARS-CoV-2 case at each individual site. This time point was
100 approximately equivalent to the start of the first UK lockdown due to Covid-19 on
101 23/3/20. Data was collected by local collaborators, and entered and stored on the
102 Research Electronic Data Capture (REDCap) server managed and hosted by the

103 University of Oxford, UK^{18,19}. Data collected included demographics, management
104 and outcomes at 6 months follow-up.

105 **Outcomes**

106 Our primary objective was to assess success of primary treatment modality, defined
107 as no additional treatment required for the index ureteric stone. Our secondary
108 objectives were to assess rates of non-operative management, ESWL, stent
109 insertion, ureteroscopy, and nephrostomy insertion; type of anaesthesia for operative
110 management options; operative complications; hospital admission and length of stay;
111 30-day and 6-month mortality; readmission, and impact of stone on renal function.

112 **Statistical analysis**

113 Statistical analysis was performed using R (version 4.1.0)²⁰. Patients in the pre-
114 pandemic cohort were compared to patients in the pandemic cohort. Two-sided
115 unpaired t-tests, and Chi-squared tests were used to analyse the data. Data is
116 presented as mean \pm standard deviation (SD) or as raw number and percentage. A
117 p-value <0.05 was deemed significant.

118 RESULTS

119 Demographics

120 Data were collected from a total of 3735 patients from 39 centres. In the pre-
121 pandemic period data were entered for 1956 patients, and in pandemic period data
122 was entered for 1779 patients. Baseline patient characteristics were broadly similar
123 (Table 1). Although, there was a significant difference in age between cohorts, the
124 median age group for both cohorts was 50-59 years.

125

126 Stone site and size were similar between cohorts (Table 1). Unexpectedly, patients
127 from the pre-pandemic cohort were reported to have significantly higher rates of
128 active infection and acute kidney injury on admission, and fever at any point during
129 index admission. However, mean C-reactive protein, white cell count, positive
130 microbiology cultures (urine or blood), and creatinine were not significantly different
131 (Table 1).

132 Management

133 Overall, patients in the pandemic period had significantly lower rates of admission to
134 hospital (pre-pandemic 54.0% vs. pandemic 46.5%, $p<0.001$) and shorter length of
135 stay in hospital (mean length of stay in days, pre-pandemic=4.1 (SD=8.0) vs.
136 pandemic=3.3 (SD=5.9), $p=0.02$) compared to the pre-pandemic period. The use of
137 alpha blockers was significantly higher during the pandemic (pre-pandemic=17.4%
138 vs. pandemic=25.4%, $p<0.001$). Despite the higher rates of active infection and
139 fever, antibiotic usage was similar between cohorts (Table 2).

140 *Interventional management*

141 There were no differences in rates of interventional management between the
142 cohorts (pre-pandemic, n=787 [40.2%] vs. pandemic, n=685 [38.5%], p=0.30), or
143 ASA grade (p=0.50) and WHO/ECOG Performance status (p=0.21) in patients who
144 received operative management (Table S1). However, there were significantly higher
145 rates of ESWL and nephrostomy insertion, and significantly lower rates of general
146 anaesthetic, ureteroscopy and stent insertion during the pandemic compared to pre-
147 pandemic (Figure 1, Table 2). During the pandemic, planned interventions were
148 delayed due to COVID-19 status in 63 out of 1580 patients (4.0%).

149 **Outcomes**

150 *30-day outcomes*

151 The 30-day operative complication rate among those who received operative
152 management was similar between the pre-pandemic and pandemic cohort (Table 2),
153 as was the 30-day mortality rate (any cause) across the whole of each cohort (pre-
154 pandemic=8 of 1793 [0.5%] vs. pandemic=9 of 1640 [0.6%], p=0.85).

155 *6-month outcomes*

156 The success rate of primary treatment (i.e. no further treatment required for the index
157 stone after primary treatment modality) was similar between cohorts (pre-
158 pandemic=73.8% vs. pandemic=76.1%, p=0.11). There was no significant difference
159 in success of primary treatment modality when stratified by treatment modality or
160 stone size.

161

162 In patients who did require further intervention, the rates of ESWL, ureteroscopy,
163 retrograde stent insertion, and nephrostomy were similar between each cohort
164 (Table 3).

165

166 The mean number of unplanned admissions (pre-pandemic=0.17 (SD=0.52) vs.
167 pandemic=0.18 (SD=0.50), $p=0.83$), mean creatinine (pre-pandemic=87.3 (SD=36.9)
168 vs. pandemic=89.4 (SD=51.9) $\mu\text{mol/L}$, $p=0.31$), and chronic kidney disease stage 1
169 to 5 (pre-pandemic=17.1% vs. pandemic=17.9%, $p=0.99$) were similar between
170 cohorts. There was a higher mortality rate in the pre-pandemic cohort group (pre-
171 pandemic=40 of 1830 [2.1%] vs. pandemic=18 of 1700 [1.1%], $p=0.01$).

172 **DISCUSSION**

173 In response to the COVID-19 pandemic, strategies to prioritise and triage patients
174 with urological pathology were developed¹². These included conservative treatment
175 whenever possible¹², and use of local-anaesthesia to minimise ventilator use and
176 reduce risk of COVID-19 exposure^{11,12,14}. If operative management was deemed
177 necessary, recommendations were made to select patients according to surgical
178 priority using patient factors (symptoms, comorbidities, and renal tract abnormalities)
179 and stone factors (obstruction, infection, and conservative management failure)^{11,12}.
180 In cases where there was an infected, obstructed system, multiple sources
181 recommended insertion of a ureteric stent under local anaesthetic as first line
182 treatment, with nephrostomy as second line option^{12,14}.

183

184 In this study, we demonstrate that the management of ureteric stones changed
185 across the UK during at the onset of the COVID-19 pandemic, with fewer invasive
186 procedures and increased rates of ESWL and medical expulsive management. We
187 also found that rates of nephrostomy were higher, despite lower rates of AKI and
188 active infection.

189

190 Other studies have reported a decrease in urological presentations during the
191 COVID-19 pandemic²¹⁻²⁴. We therefore predicted that during the pandemic patients
192 with ureteric colic would have delayed presenting to hospital and therefore have
193 been a more unwell cohort. However, in our data, rates of AKI and active infection
194 were lower in the pandemic patient cohort suggesting that these patients did not
195 delay their presentation long enough to impact their clinical condition. These findings
196 contrast with other urolithiasis datasets. Castellani et al. compared ureteric stone

197 disease outcomes of 298 patients prior to the pandemic with 218 patients during the
198 pandemic, reporting reduced admissions and higher rates of infected-obstructed
199 systems, hospitalisation, and intervention during the COVID-19 pandemic²⁵.

200 Furthermore, Flammia et al. found that serum creatinine was significantly higher in
201 36 patients with urinary stone emergencies during the pandemic compared to 44
202 patients with urinary stone emergencies prior to the pandemic, which the authors
203 posited was due to delayed presentation²⁶. Similarly, Gul et al. demonstrated an
204 increase in creatinine, white cell count, hospital admissions, antibiotic treatment, and
205 emergency nephrostomy insertion in 35 patients with urolithiasis during the
206 pandemic compared to 114 patients with urolithiasis prior to the pandemic²⁷.

207

208 Our findings are consistent with those reported by Anderson et al. and Nourian et al.
209 who identified no difference in markers of infection or AKI between pre-pandemic
210 and post-pandemic cohorts of patients presenting with urolithiasis^{28, 29}. Our study
211 represents the largest cohort to date investigating ureteric stone outcomes during the
212 pandemic, has a multicentre design and had a pre-defined protocol. Thus, we predict
213 our findings are representative of true outcomes in the UK during the COVID-19
214 pandemic.

215

216 Steinberg et al. suggested that we can use the COVID-19 pandemic as an
217 opportunity to reassess ureteric stone management strategies, and establish
218 whether conservative management strategies have been under-used³⁰. Our study is
219 the first to evaluate the impact of changes in the management of ureteric stones
220 during the COVID-19 pandemic on patient outcomes at 6 month follow up^{26,28,29,31,32}.

221 We demonstrate that increased use of conservative management strategies did not

222 have a detrimental effect on primary treatment success or patient outcomes at 6-
223 month follow up. Our data supports increased use of less-invasive options
224 recommended by NICE guidance including watchful waiting with medical expulsive
225 therapy and ESWL as first line – there was an approximately 10% shift from URS to
226 ESWL during the pandemic with non-inferior outcomes. Our data also support a
227 reduction in admission rates and earlier discharge. It is unclear whether these
228 changes will revert once the pandemic stabilises and patient backlog is tackled or if
229 practice will change permanently. Evidence such as this should drive a more
230 permanent change to less-invasive management, as the change in practice during
231 the pandemic has shown that this is safe and as effective.

232

233 This study is the first of its kind to be conducted across multiple sites with 6-month
234 follow-up. However, the study is limited by its retrospective design, and missing data.
235 Our study was conducted across 39 centres and the number of cases entered by
236 each centre varied considerably. This may be due to differences in local patient
237 populations, however, it may be that not all patients within each time period were
238 captured. This increases the risk of selection bias within our study and therefore no
239 comment can be made on whether there was a change in the number of
240 presentations with ureteric stone disease during each time period.

241 **CONCLUSIONS**

242 As a result of the COVID-19 pandemic patients in the UK with ureteric stones were
243 less likely to be treated invasively and more likely to be managed without admission.
244 However, this change in practice did not result in inferior outcomes for patients. The
245 pandemic has given the urological community an opportunity to re-evaluate
246 management of ureteric stones; our findings indicate that a greater proportion of
247 ureteric stones can be managed safely and effectively with non-invasive ambulatory
248 options.

249 REFERENCES

- 250 1. Heers H, Turney BW. Trends in urological stone disease: a 5-year update of
251 hospital episode statistics. *BJU Int.* 2016;118(5):785-789.
252 doi:10.1111/bju.13520
- 253 2. Scales CD, Smith AC, Hanley JM, Saigal CS. Prevalence of Kidney Stones in
254 the United States. *Eur Urol.* 2012;62(1):160-165.
255 doi:10.1016/j.eururo.2012.03.052
- 256 3. Geraghty RM, Cook P, Walker V, Somani BK. Evaluation of the economic
257 burden of kidney stone disease in the UK: a retrospective cohort study with a
258 mean follow-up of 19 years. *BJU Int.* 2020;125(4):586-594.
259 doi:10.1111/bju.14991
- 260 4. Shah TT, Gao C, Peters M, et al. Factors associated with spontaneous stone
261 passage in a contemporary cohort of patients presenting with acute ureteric
262 colic: results from the Multi-centre cohort study evaluating the role of
263 Inflammatory Markers In patients presenting with acute ureteric. *BJU Int.*
264 2019;124(3):504-513. doi:10.1111/bju.14777
- 265 5. PEARLE MS, PIERCE HL, MILLER GL, et al. OPTIMAL METHOD OF
266 URGENT DECOMPRESSION OF THE COLLECTING SYSTEM FOR
267 OBSTRUCTION AND INFECTION DUE TO URETERAL CALCULI. *J Urol.*
268 1998;160(4):1260-1264. doi:10.1016/S0022-5347(01)62511-4
- 269 6. NICE guideline NG118: Renal and ureteric stones: Assessment and
270 management.
- 271 7. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. *Acta Biomed.*
272 2020;91(1):157-160. doi:10.23750/abm.v91i1.9397
- 273 8. COVIDSurg Collaborative . Elective surgery cancellations due to the COVID-


- 274 19 pandemic: global predictive modelling to inform surgical recovery plans. *Br*
275 *J Surg.* June 2020. doi:10.1002/bjs.11746
- 276 9. Nepogodiev D, Bhangu A, Glasbey JC, et al. Mortality and pulmonary
277 complications in patients undergoing surgery with perioperative SARS-CoV-2
278 infection: an international cohort study. *Lancet.* 2020;396(10243):27-38.
279 doi:10.1016/S0140-6736(20)31182-X
- 280 10. Royal College of Surgeons of England. Updated Inter-collegiate General
281 Surgery Guidance on COVID-19. London: Royal College of Surgeons of
282 England.
- 283 11. Metzler IS, Sorensen MD, Sweet RM, Harper JD. Stone Care Triage During
284 COVID-19 at the University of Washington. *J Endourol.* 2020;34(5):539-540.
285 doi:10.1089/end.2020.29080.ism
- 286 12. Proietti S, Gaboardi F, Giusti G. Endourological Stone Management in the Era
287 of the COVID-19. *Eur Urol.* 2020;78(2):131-133.
288 doi:10.1016/j.eururo.2020.03.042
- 289 13. Thornton J. Covid-19: A&E visits in England fall by 25% in week after
290 lockdown. *BMJ.* April 2020:m1401. doi:10.1136/bmj.m1401
- 291 14. Stensland KD, Morgan TM, Moinzadeh A, et al. Considerations in the Triage of
292 Urologic Surgeries During the COVID-19 Pandemic. *Eur Urol.* 2020;77(6):663-
293 666. doi:10.1016/j.eururo.2020.03.027
- 294 15. Georgiades F, Byrne MH, Lovegrove CE, et al. The COVID Stones
295 Collaborative: How has the Management of Ureteric Stones Changed During
296 and After the COVID-19 Pandemic? Rationale and Study Protocol. *J*
297 *Endoluminal Endourol.* 2020;3(3):e22-e28. doi:10.22374/JELEU.V3I3.96
- 298 16. Blencowe N, Glasbey J, Heywood N, et al. Recognising contributions to work

- 299 in research collaboratives: Guidelines for standardising reporting of authorship
300 in collaborative research. *Int J Surg*. 2018;52:355-360.
301 doi:10.1016/J.IJSU.2017.12.019
- 302 17. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke
303 JP. The Strengthening the Reporting of Observational Studies in Epidemiology
304 (STROBE) statement: guidelines for reporting observational studies. *Lancet*.
305 2007;370(9596):1453-1457. doi:10.1016/S0140-6736(07)61602-X
- 306 18. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research
307 electronic data capture (REDCap)—A metadata-driven methodology and
308 workflow process for providing translational research informatics support. *J*
309 *Biomed Inform*. 2009;42(2):377-381. doi:10.1016/j.jbi.2008.08.010
- 310 19. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an
311 international community of software platform partners. *J Biomed Inform*.
312 2019;95:103208. doi:10.1016/j.jbi.2019.103208
- 313 20. R Core Team. R: A language and environment for statistical computing. 2017.
314 <https://www.r-project.org/>.
- 315 21. Madanelo M, Ferreira C, Nunes-Carneiro D, et al. The impact of the
316 coronavirus disease 2019 pandemic on the utilisation of emergency urological
317 services. *BJU Int*. 2020;126(2):256-258. doi:10.1111/BJU.15109
- 318 22. Motterle G, Morlacco A, Iafrate M, et al. The impact of COVID-19 pandemic on
319 urological emergencies: a single-center experience. *World J Urol*. 2021;39(6).
320 doi:10.1007/S00345-020-03264-2
- 321 23. Porreca A, Colicchia M, D'Agostino D, et al. Urology in the Time of
322 Coronavirus: Reduced Access to Urgent and Emergent Urological Care during
323 the Coronavirus Disease 2019 Outbreak in Italy. *Urol Int*. 2020;104(7-8):631-

- 324 636. doi:10.1159/000508512
- 325 24. Korkes F, Smaidi K, Salles MP, Neto ACL, Heilberg IP, Glina S. COVID-19:
326 The impact on urolithiasis treatment in Brazil. *Int Braz J Urol.* 2022;48(1):101-
327 109. doi:10.1590/S1677-5538.IBJU.2021.0405
- 328 25. Castellani D, Ragonese M, Di Rosa M, et al. An Italian multicenter analysis of
329 emergency admissions and treatment of upper tract urolithiasis during the
330 lockdown and reopening phases of the COVID-19 pandemic: Are we ready for
331 a second wave of the outbreak? *Int J Urol.* 2021;28(9):950.
332 doi:10.1111/IJU.14612
- 333 26. Flammia S, Salciccia S, Tufano A, Busetto GM, Ricciuti GP, Sciarra A. How
334 urinary stone emergencies changed in the time of COVID-19? *Urolithiasis.*
335 2020;48(5):467-469. doi:10.1007/s00240-020-01198-3
- 336 27. Gul M, Kaynar M, Yildiz M, et al. The Increased Risk of Complicated Ureteral
337 Stones in the Era of COVID-19 Pandemic. *J Endourol.* 2020;34(8):882-886.
338 doi:10.1089/end.2020.0658
- 339 28. Anderson S, McNicholas D, Murphy C, et al. The impact of COVID-19 on acute
340 urinary stone presentations: a single-centre experience. *Ir J Med Sci.*
341 2022;191(1):45-49. doi:10.1007/S11845-021-02562-X
- 342 29. Nourian A, Uppaluri C, Chen M, Ghiraldi EM, Friedlander JI. Comparison of
343 Management and Outcomes of Symptomatic Urolithiasis During the COVID-19
344 Pandemic to a Comparative Cohort. *Urology.* 2022.
345 doi:10.1016/J.UROLOGY.2022.01.019
- 346 30. Steinberg RL, Johnson BA, Antonelli J, Pearle MS. Urolithiasis in the COVID
347 Era: An Opportunity to Reassess Management Strategies. *Eur Urol.*
348 2020;78(6):777. doi:10.1016/J.EURURO.2020.07.019

- 349 31. Liu Z, Man L. Impacts of the COVID-19 outbreak on visits and treatments for
350 patients with ureteral stones in a general hospital emergency department. *Urol*
351 *J.* 2021;88(3):232-236. doi:10.1177/0391560320985659
- 352 32. Gökçe Mİ, Yin S, Sönmez MG, et al. How does the COVID-19 pandemic affect
353 the preoperative evaluation and anesthesia applied for urinary stones? EULIS
354 eCORE–IAU multicenter collaborative cohort study. *Urolithiasis.*
355 2020;48(4):345-351. doi:10.1007/s00240-020-01193-8
356

357 **FIGURE CAPTIONS**



358

359

Figure 1: Change in interventional management during the pandemic

360 **TABLE CAPTIONS**

	Pre-pandemic period (N=1956)	Pandemic period (N=1779)	p-value
Age group			0.02
18-19 years	11 (0.6%)	17 (1.0%)	
20-29 years	198 (10.1%)	164 (9.2%)	
30-39 years	340 (17.4%)	346 (19.4%)	
40-49 years	361 (18.5%)	359 (20.2%)	
50-59 years	409 (20.9%)	405 (22.8%)	
60-69 years	336 (17.2%)	267 (15.0%)	
70-79 years	210 (10.7%)	149 (8.4%)	
80+ years	90 (4.6%)	72 (4.1%)	
Gender			0.823
Female	576 (29.4%)	517 (29.1%)	
Male	1380 (70.6%)	1262 (70.9%)	
BMI			
Mean (SD)	28.8 (6.3)	29.6 (7.4)	0.074
Median [IQR]	28.0 [24.4-32.1]	28.7 [24.7-32.9]	
Non-urological comorbidities			0.075
Yes	538 (36.2%)	453 (32.9%)	
No	950 (63.8%)	923 (67.1%)	
Urological comorbidities			0.662
Yes	56 (3.8%)	46 (3.4%)	
No	1429 (96.2%)	1309 (96.6%)	
Ureteric stone location?			0.52
Left	1014 (51.8%)	929 (52.2%)	
Right	873 (44.6%)	799 (44.9%)	
Bilateral	69 (3.53%)	51 (2.87%)	
Maximum stone size (mm)			0.687
≤5	1026 (57.5%)	926 (56.9%)	
6-10	633 (35.5%)	598 (36.8%)	
11-19	108 (6.1%)	85 (5.2%)	
≥20	18 (1.0%)	17 (1.1%)	
Active infection at time of presentation			0.032
Yes	258 (13.2%)	193 (10.8%)	
No	1697 (86.8%)	1586 (89.2%)	
Fever (Temperature >38 degree C) at any stage in index admission			0.031
Yes	151 (9.3%)	107 (7.1%)	
No	1482 (90.8%)	1406 (92.9%)	
Admission blood tests CRP (mg/L)			0.562
Mean (SD)	27.7 (64.6)	26.4 (68.7)	
Median [IQR]	4.0 [1.0-17.0]	3.0 [1.0-13.0]	
Admission blood tests WCC (x10⁹/L)			0.725

	Pre-pandemic period (N=1956)	Pandemic period (N=1779)	p-value
Mean (SD)	11.0 (6.2)	11.0 (4.2)	
Median [IQR]	10.3 [8.1-12.9]	10.7 [8.1-13.1]	
Positive blood culture			0.749
Yes	51 (38.1%)	41 (41.0%)	
No	83 (61.9%)	59 (59.0%)	
Positive urine culture (>10⁵ cfu)			0.796
Yes	97 (21.8%)	78 (20.9%)	
No	347 (78.2%)	296 (79.1%)	
Admission blood tests Creatinine (umol/L)			0.765
Mean (SD)	105 (70.8)	106 (75.9)	
Median [IQR]	94.0 [77.0-113.0]	93.0 [78.0-113.0]	
AKI			0.041
Yes	340 (21.9%)	290 (18.9%)	
No	1211 (78.1%)	1245 (81.1%)	
AKI Grade (KGIDO)			
Grade 1	226 (74.1%)	202 (74.8%)	
Grade 2	55 (18.0%)	44 (16.3%)	
Grade 3	24 (7.9%)	24 (8.9%)	

361 *Table 1: baseline characteristics between the pre-pandemic patient cohort and the*
362 *pandemic patient cohort. AKI = acute kidney injury CFU = colony forming units; CRP*
363 *= C reactive protein; IQR = interquartile range; SD = standard deviation; WCC =*
364 *white cell count.*

365

366

	Pre-pandemic period (N=1956)	Pandemic period (N=1779)	P-value
Admitted to hospital?			<0.001
Yes	1057 (54.0%)	827 (46.5%)	
No	899 (46.0%)	952 (53.5%)	
Length of stay (days)			0.021
Mean (SD)	4.08 (8.04)	3.29 (5.94)	
Alpha blocker			<0.001
Yes	316 (17.4%)	414 (25.4%)	
No	1501 (82.6%)	1219 (74.6%)	
Antibiotics			
Yes-Oral	171 (8.74%)	148 (8.32%)	0.251
Yes-IV	304 (15.5%)	245 (13.8%)	
No	1481 (75.7%)	1386 (77.9%)	
Interventional management			0.295
Yes	787 (40.2%)	685 (38.5%)	
No	1169 (59.8%)	1094 (61.5%)	
	Pre-pandemic period (N=787)	Pandemic period (N=685)	P-value
Anaesthetic			<0.001
General	390 (92.2%)	173 (76.2%)	
Non-general	33 (7.80%)	54 (23.8%)	
ESWL for index stone			<0.001
Yes	179 (22.7%)	233 (34.1%)	
No	608 (77.3%)	451 (65.9%)	

Ureteroscopy for index stone			<0.001
Yes	450 (57.2%)	325 (47.5%)	
No	337 (42.8%)	359 (52.5%)	
Stent insertion for index stone (alone or as part of Ureteroscopy)			<0.001
Yes	538 (68.4%)	374 (54.6%)	
No	249 (31.6%)	311 (45.4%)	
Emergency nephrostomy insertion for index stone			0.027
Yes	56 (7.1%)	72 (10.5%)	
No	731 (92.9%)	613 (89.5%)	
Operative complication			0.616
Yes	87 (11.5%)	68 (10.5%)	
No	671 (88.5%)	580 (89.5%)	
30-day highest Clavien-Dindo grade			
None	671 (88.5%)	580 (89.5%)	
I	44 (5.8%)	28 (4.3%)	
II	29 (3.8%)	15 (2.3%)	
III-A	1 (0.1%)	8 (1.2%)	
III-B	9 (1.2%)	12 (1.9%)	
IV-A	2 (0.3%)	0 (0.0%)	
IV-B	1 (0.1%)	2 (0.3%)	
V (death)	1 (0.1%)	3 (0.5%)	

367 *Table 2: Management and complications*

368

369

	Pre-pandemic period (N=1956)	Pandemic period (N=1779)	P-value
Primary treatment success			0.113
Yes	1379 (73.8%)	1308 (76.1%)	
No	490 (26.2%)	410 (23.9%)	
Unplanned readmission for ureteric stone disease			0.826
Mean (SD)	0.173 (0.520)	0.176 (0.500)	
Creatinine (umol/L)			0.305
Mean (SD)	87.3 (36.9)	89.4 (51.9)	
CKD			0.989
Yes	230 (17.2%)	213 (17.1%)	
No	1111 (82.8%)	1036 (82.9%)	
Death			0.014
Yes	40 (2.14%)	18 (1.05%)	
No	1830 (97.9%)	1700 (99.0%)	
Additional interventions			
ESWL			0.231
Yes	87 (4.9%)	95 (5.8%)	
No	1689 (95.1%)	1519 (94.1%)	
Ureterscopy +/- Laser lithotripsy +/- Stent insertion			0.072
Yes	358 (19.5%)	288 (17.1%)	
No	1481 (80.5%)	1400 (82.9%)	
Stent insertion retrograde			0.62
Yes	84 (4.8%)	69 (4.3%)	
No	1685 (95.3%)	1524 (95.7%)	

Nephrostomy insertion 0.782

Yes	17 (1.0%)	13 (0.8%)
No	1767 (99.0%)	1602 (99.2%)

370

371 *Table 3: Outcomes and additional operative management required at 6 months*

372 *follow-up.*

373 **SUPPLEMENTARY TABLES**

	Pre-pandemic period (N=787)	Pandemic period (N=685)	P-value
ASA grade			
1. A normal healthy patient	219 (42.0%)	134 (43.4%)	0.498
2. A patient with mild systemic disease	199 (38.1%)	125 (40.5%)	
3. A patient with severe systemic disease	89 (17.0%)	45 (14.6%)	
4. A patient with severe systemic disease that is a constant threat to life	15 (2.87%)	5 (1.62%)	
WHO/ECOG Performance status			
Fully active, able to carry on all pre-disease activities	326 (73.1%)	211 (75.9%)	0.214
Restricted in physical strenuous activity, able to perform light work	87 (19.5%)	39 (14.0%)	
Ambulatory and capable of all self-care, unable to work	18 (4.04%)	15 (5.40%)	
Capable of limited self-care only	11 (2.47%)	7 (2.52%)	
Completely disabled. Confined to bed or chair	4 (0.897%)	6 (2.16%)	

374 *Table S1: ASA Grade and WHO/ECOG Performance status*

375